Advanced Search:
Equity Index

BIOS.BR - BIOSENIC

€0.01  -0.0008 (-5.13%)

Updated: 07:02 May 5, 2024 EST

Next Session's AI Forecast

-568.17%

Avg. Accuracy (AI)

€-0.14

Next Week's AI Forecast

100%

Trend's Accuracy (AI)

€-0.01

BIOSENIC's Position Within the Biotechnology Industry
0 (Bottom)
100 (Top) Data Normalization
Rank (0-100)
0 (Bottom)
100 (Top) Data Normalization
Rank (0-100)

BIOSENIC - HISTORICAL DATA 6M

  • Last price

    €0.01

  • Daily change

    €-0.0008

  • Previous Close

    €0.0156

  • Last Updated

    07:02 May 5, 2024 EST

CURRENT VOLATILITY

Curr. Week Curr. Month Curr. Quarter Next Quarter Curr Year
-0.51 -3.4 -1.81 -1.16 -1.04

CURRENT VOLATILITY RANK

Variation from the lowest to the highest value in a period.

Curr. Week Curr. Month Curr. Quarter Next Quarter Curr Year
4.52 5.21 4.95 5.57 5.95

STOCHASTIC METRIC

The STOCHASTIC METRIC shows when a financial asset has moved into an overbought or oversold position.

OVERSOLD
OVERBOUGHT
Curr. Week Next Week Curr. Month Curr. Quarter
18.18% 10.53% 1.85% 0.86%

MOVING AVERAGE METRIC

5 Sessions Change 5 Sessions 20 Sessions Change 20 Sessions 50 Sessions Change 50 Sessions 200 Sessions
0.01 -50% 0.02 0% 0.02 -50% 0.04

RSI METRIC

RS Hour RSI Hour RS Day RSI Day
N/A N/A N/A N/A

BIOSENIC Technical Analysis News

BIOSENIC

Building H (box 24)
Rue GranbonprE 11
Mont-Saint-Guibert 1435
Belgium
32 493 09 73 66
https://www.biosenic.com

Sectors: Healthcare
Industry: Biotechnology
Description

BioSenic S.A., a biotech company, focuses on developing clinical assets. Its technologies include cutting-edge allogeneic cell and gene therapy platform with differentiated bone marrow sourced mesenchymal stromal cells, which can be stored at the point of use in the hospital; and Arsenic TriOxide platform for use in immuno-oncology to treat graft-versus-host disease, systemic lupus erythematosus, and systemic sclerosis. The company's investigational medicinal product is ALLOB, which is in a Phase IIb clinical trial in patients with difficult tibial fractures' and ArsciCor, which is in Phase III in GvHD is being prepared with an oral treatment. BioSenic S.A. is based in Mont-Saint-Guibert, Belgium.

Corporate Governance

BioSenic S.A.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.